Hypertrophic cardiomyopathy in pediatric practice: a discussion on the association with COVID-19
https://doi.org/10.22627/2072-8107-2026-25-1-33-36
Abstract
It has been proven that the SARS-CoV-2 virus can initiate the development of a number of post-infectious complications in children, including cardiovascular and thrombotic complications, which are clearly demonstrated in the clinical case of heart transplantation, which is an extremely relevant practice for doctors of all specialties. Objective: to describe a clinical case of heart transplantation in a child who had COVID-19. The article presents a general understanding of the pathogenetically bidirectional relationship between the new coronavirus infection and cardiovascular complications, and provides a clinical case of heart transplantation in a 17-year-old child who had COVID-19. The clinical case we presented confirms the existence of a pathogenetically determined relationship between COVID-19 and cardiovascular complications. To better understand the mechanisms underlying the development of cardiovascular disorders, it is necessary to create a unified Global Registry of patients with cardiac complications after COVID-19.
About the Authors
V. V. SokolovskayaRussian Federation
Smolensk
A. A. Litvinova
Russian Federation
Smolensk
O. O. Ovchinnikova
Russian Federation
Smolensk
M. Yu. Sorochkina
Russian Federation
Smolensk
T. V. Kristalinskaya
Russian Federation
Smolensk
References
1. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583—590. doi:10.1038/s41591-022-01689-3
2. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601—615. doi:10.1038/s41591-021-01283-z
3. Akhmedova EE, Kozhevnikova OV, Abashidze EA, Logacheva OS, Paltseva AE. Izmeneniya elektrogrammy u detey s oslozhnennym techeniem COVID-19 [Electrogram changes in children with complicated COVID-19]. Rossiiskii Pediatricheskii Zhurnal. 2021;24(Suppl):11. (In Russ.)
4. Say D, Crawford N, McNab S, Wurze D, Steer A, Tosif S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. Lancet Child Adolesc Health. 2021;5(6):22—23. doi:10.1016/S2352-4642(21)00124-3
5. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503— 3626. doi:10.1093/eurheartj/ehad194
6. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/ SCMR Guideline for the Management of Hypertrophic Cardiomyopathy. Circulation. 2024;149(23):e1239—e1311. doi:10.1161/CIR.0000000000001250
7. Lopes LR, Ho CY, Elliott PM. Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice. Eur Heart J. 2024;45(30):2727—2734. doi:10.1093/eurheartj/ehae421
8. Ireland CG, Ho CY. Genetic Testing in Hypertrophic Cardiomyopathy. Am J Cardiol. 2024;212S:S4—S13. doi:10.1016/j.amjcard.2023.10.032
9. Bakalakos A, Monda E, Elliott PM. The Diagnostic and Therapeutic Implications of Phenocopies and Mimics of Hypertrophic Cardiomyopathy. Can J Cardiol. 2024;40(5):754—765. doi:10.1016/j.cjca.2024.02.025
10. Tsai EJ, Ciháková D, Tucker NR. Cell-Specific Mechanisms in the Heart of COVID-19 Patients. Circ Res. 2023;132(10):1290—1301. doi:10.1161/CIRCRESAHA.123.321876
11. Shao X, Zeng Q, Liu S, et al. Pathogenic mechanisms of cardiovascular damage in COVID-19. Mol Med Rep. 2024.
Review
For citations:
Sokolovskaya V.V., Litvinova A.A., Ovchinnikova O.O., Sorochkina M.Yu., Kristalinskaya T.V. Hypertrophic cardiomyopathy in pediatric practice: a discussion on the association with COVID-19. CHILDREN INFECTIONS. 2026;25(1):33-36. (In Russ.) https://doi.org/10.22627/2072-8107-2026-25-1-33-36
JATS XML




































